Recombinant Anti-Ceruloplasmin antibody [EPSISR6-42] (ab157452)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPSISR6-42] to Ceruloplasmin
- Suitable for: ICC/IF, WB
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Ceruloplasmin antibody [EPSISR6-42]
See all Ceruloplasmin primary antibodies -
Description
Rabbit monoclonal [EPSISR6-42] to Ceruloplasmin -
Host species
Rabbit -
Tested applications
Suitable for: ICC/IF, WBmore details
Unsuitable for: IHC-P or IP -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- Human plasma and serum; HepG2 cells.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20ºC. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 40% Glycerol (glycerin, glycerine), 0.05% BSA, 9% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPSISR6-42 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab157452 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ICC/IF |
1/100 - 1/250.
|
|
WB |
1/1000 - 1/5000. Predicted molecular weight: 122 kDa.
|
Notes |
---|
ICC/IF
1/100 - 1/250. |
WB
1/1000 - 1/5000. Predicted molecular weight: 122 kDa. |
Target
-
Function
Ceruloplasmin is a blue, copper-binding (6-7 atoms per molecule) glycoprotein. It has ferroxidase activity oxidizing Fe(2+) to Fe(3+) without releasing radical oxygen species. It is involved in iron transport across the cell membrane. -
Tissue specificity
Expressed by the liver and secreted in plasma. -
Involvement in disease
Defects in CP are the cause of aceruloplasminemia (ACERULOP) [MIM:604290]. It is an autosomal recessive disorder of iron metabolism characterized by iron accumulation in the brain as well as visceral organs. Clinical features consist of the triad of retinal degeneration, diabetes mellitus and neurological disturbances.
Note=Ceruloplasmin levels are decreased in Wilson disease, in which copper cannot be incorporated into ceruloplasmin in liver because of defects in the copper-transporting ATPase 2. -
Sequence similarities
Belongs to the multicopper oxidase family.
Contains 3 F5/8 type A domains.
Contains 6 plastocyanin-like domains. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 1356 Human
- Omim: 117700 Human
- SwissProt: P00450 Human
- Unigene: 558314 Human
-
Alternative names
- CERU_HUMAN antibody
- Ceruloplasmin antibody
- CP 2 antibody
see all
Images
-
All lanes : Anti-Ceruloplasmin antibody [EPSISR6-42] (ab157452) at 1/1000 dilution
Lane 1 : Human plasma cell lysate
Lane 2 : Human serum cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 122 kDa -
Immunofluorescent analysis of HepG2 cells labeling Ceruloplasmin with ab157452 at 1/100 dilution.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (1)
ab157452 has been referenced in 1 publication.
- Xiao Q et al. LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRß signaling. Int J Oncol 53:1069-1082 (2018). PubMed: 30015847